United States 119th Congress Status: In Committee Bipartisan · 2 D · 1 R cosponsors

HR 1244 — Reducing Drug Prices for Seniors Act

Last action — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced February 12, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Prognosis

Advancing 36% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 3 sponsors

    1 primary, 2 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (2 D · 1 R) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

In plain language

HR 1244 is a bill recently introduced in the House for committee review.

HR 1244 was introduced in the House and is currently being reviewed by two committees. The committees will consider its provisions related to their jurisdiction.

Summary

Reducing Drug Prices for Seniors ActThis bill requires the coinsurance amount for covered drugs under the Medicare prescription drug benefit to be based on the actual acquisition cost of the drug (i.e., the negotiated price under the prescription drug plan net of any manufacturer price concessions), rather than the wholesale acquisition cost of the drug, if the actual acquisition cost is lower.

Bill Text

How this bill changes current law

4 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill amends the calculation of coinsurance for Medicare Part D drugs to be based on the actual acquisition cost rather than the wholesale acquisition cost.

  • 42 U.S.C. 1395w-102

    and (9) → , (9), and (10)

    This change expands the existing list of requirements to include a new requirement regarding coinsurance calculations.

  • 42 U.S.C. 1395w-102

    (10) Requirement that coinsurance for covered part d drugs be based on the actual acquisition cost of the drug.--(A) In general.--For plan years beginning on or after January 1, 2026, for costs above the annual deductible specified in paragraph (1) and below the annual out-of-pocket threshold specified in paragraph (4), any coinsurance amount for a covered part D drug (insofar as such covered part D drug is included on the formulary and subject to coinsurance rather than a copayment) shall be calculated based on the actual acquisition cost (and not the wholesale acquisition cost) of such covered part D drug if such actual acquisition cost is lower than the wholesale acquisition cost of such covered part D drug. The preceding sentence shall not apply to a covered part D drug described in paragraph (8) or (9).

    This addition establishes a new requirement for coinsurance calculations under Medicare Part D, ensuring they are based on the lower of the actual acquisition cost or the wholesale acquisition cost.

  • 42 U.S.C. 1395w-102

    (B) Actual acquisition cost defined.--In this paragraph, the term 'actual acquisition cost' means, with respect to a covered part D drug, the negotiated price of the covered part D drug under the prescription drug plan or MA-PD plan, net of any manufacturer-provided price concessions (as defined under section 423.100 of title 42, Code of Federal Regulations (or any successor regulation)), as reported for such drug in the Detailed DIR Report (or any successor report) submitted by the sponsor or organization offering the plan for the previous plan year.

    This definition clarifies what is meant by 'actual acquisition cost' for the purpose of calculating coinsurance under Medicare Part D.

  • 42 U.S.C. 1395w-102

    (7) Requirement that coinsurance for covered part d drugs be based on the net price of the drug.--The coverage is provided in accordance with subsection (b)(10).

    This additional paragraph ties the new coinsurance requirement back to the main provisions on coverage, reinforcing the change.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  4. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 2 co-sponsors · 544 not signed on

Sponsors (1)

Co-sponsors (2)

Not signed on (544)

544 members have not signed on to this bill.

Show all 544 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 1244 do?
Reducing Drug Prices for Seniors ActThis bill requires the coinsurance amount for covered drugs under the Medicare prescription drug benefit to be based on the actual acquisition cost of the drug (i.e., the negotiated price under the prescription drug plan net of any manufacturer price concessions), rather than the wholesale acquisition cost of the drug, if the actual acquisition cost is lower.
Who sponsors HR 1244?
HR 1244 is sponsored by Davis, Donald G. (Democratic), Pfluger, August (Republican), and Harder, Josh (Democratic).
What is the current status of HR 1244?
This bill is in committee in the House. Introduced February 12, 2025. It must pass committee before a floor vote.
Where can I track HR 1244?
Track HR 1244 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 1244

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 1244

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →